PPIDT00366
Drug Information
| Name | Coagulation factor VII human |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB13150 |
| Type | biotech |
| Indication | May be administered in cases of uncontrolled bleeding. Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. Off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage. Brands for human factor VII are currently only in combination with other vitamin K coagulation factors and can be used to reverse vitamin K antagonist activity in patients with acute major bleeds or for urgent surgery/invasive procedures. Along with other blood coagulation factors, it is used to reverse acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with a need for an urgent surgery/invasive procedure.[L50517] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
|
| Injection | Intravenous |
|
| Injection, powder, lyophilized, for solution | Intravenous |
60000000 IU
|
| Injection, powder, for solution | Parenteral |
600 I.E.
|
| Powder, for solution | Intravenous |
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
|
| Kit; powder, for solution | Intravenous |
|
| Injection, powder, for solution | Intravenous drip |
520 IU/vial
|
| Injection, powder, for solution | Parenteral |
|
| Injection, powder, lyophilized, for solution | Intravenous |
200 IU/10ml
|
| Injection, powder, lyophilized, for solution | Intravenous |
500 IU/10ml
|
| Powder, for solution | Intravenous |
200 UI
|
| Powder, for solution | Intravenous |
600 UI
|